Optimal Management of Stage II Seminoma: Preventing Harm While Preserving Cure.
1/5 보강
Stage II testicular seminoma is highly curable when treated using standard-of-care cisplatin-based chemotherapy or radiotherapy.
APA
Conduit C, Bagrodia A, et al. (2026). Optimal Management of Stage II Seminoma: Preventing Harm While Preserving Cure.. JCO oncology practice, 22(2), 207-215. https://doi.org/10.1200/OP-25-00252
MLA
Conduit C, et al.. "Optimal Management of Stage II Seminoma: Preventing Harm While Preserving Cure.." JCO oncology practice, vol. 22, no. 2, 2026, pp. 207-215.
PMID
40513041 ↗
Abstract 한글 요약
Stage II testicular seminoma is highly curable when treated using standard-of-care cisplatin-based chemotherapy or radiotherapy. However, these treatments can affect long-term quality of life because of the development long-term, or chronic, toxicities and late effects. In recent years, multiple emerging treatment strategies for stage II seminoma have been explored with the principal aim of minimizing toxicity in this young patient population. These strategies have included cisplatin-sparing chemotherapy, combined modality chemoradiotherapy, and surgery in the form of primary retroperitoneal lymph node dissection; small cohort studies for each approach have reported promising efficacy with minimal toxicity, albeit without long-term follow up. While there is a need to optimize and rationalize treatment to ensure that quality of life is front of mind, it is essential that the excellent outcomes using standard-of-care treatment are not taken for granted and that cure is not compromised for young patients with stage II seminoma. This review assesses the relative merits and deficiencies of each emerging treatment strategy, with one lens focused on preventing harm and the other focused on preserving disease control and cure.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.